Celebrity endorsements are nothing new in pharmaceutical advertising. However, Supernus Pharmaceuticals is taking a different approach with Olympic snowboarder Chloe Kim. Its latest Qelbree campaign shows how partnerships with trusted publishers and social platforms can turn a celebrity spokesperson into a powerful distribution strategy.
Rather than relying on traditional commercials, Supernus is connecting Kim’s personal ADHD experience with fashion, wellness, and social storytelling. The result offers a useful lesson for pharmaceutical marketers: The right spokesperson can do more than attract attention. She can connect an entire media ecosystem.
Table of Contents
- How Chloe Kim Became Qelbree’s Distribution Strategy
- Why Publisher Partnerships Matter in Pharma Marketing
- How Social Media Extends the Campaign’s Reach
- What Pharmaceutical Marketers Can Learn
- Conclusion
- Frequently Asked Questions
How Chloe Kim Became Qelbree’s Distribution Strategy
Supernus Pharmaceuticals expanded its “Ms. Represented” campaign on October 28, 2026, featuring Chloe Kim, a two-time Olympic gold medalist who received an ADHD diagnosis as an adult.
Kim is also a Qelbree user and paid spokesperson. Her participation builds on the campaign’s original work with actress Busy Philipps, who shared her own experience of receiving an ADHD diagnosis later in life.
The campaign addresses a significant awareness gap. According to Supernus Pharmaceuticals’ announcement, more than 60% of U.S. women who reported an ADHD diagnosis received it during adulthood.
For pharmaceutical marketers, the interesting development goes beyond the celebrity partnership itself.
Kim brings several interests into one campaign. Her identity as an athlete connects with sports audiences, while her fashion interests create opportunities for lifestyle coverage. Meanwhile, her personal experience with ADHD supports conversations about mental health.
Consequently, Supernus can introduce the same spokesperson across multiple audience groups without repeating an identical advertisement.
The strategy moves beyond buying celebrity recognition. Instead, it uses an authentic personal story to connect different media environments under one campaign.
Why Publisher Partnerships Matter in Pharma Marketing
The campaign’s most distinctive feature is its use of editorial partnerships.
Supernus is working with Coveteur, PureWow, and NowThis to introduce Kim’s story through formats that already appeal to their audiences.
Coveteur, a fashion and lifestyle publication owned by Gallery Media Group, is featuring Kim in a digital cover story that connects her personal style, creativity, and ADHD experience.
Meanwhile, PureWow is incorporating her story into its wellness-focused “check-in” content franchise. This placement introduces the discussion within a familiar lifestyle setting rather than a conventional pharmaceutical advertisement.
NowThis brings another dimension through its social-first “Are You Okay?” interview series. The conversational format creates room for Kim to discuss her experience with ADHD in a way that suits younger digital audiences.
Each partnership serves a different purpose.
Coveteur offers fashion relevance, PureWow provides a wellness setting, and NowThis supports personal conversations designed for social sharing.
This is where publisher-led pharma marketing becomes especially valuable. Rather than forcing audiences into a single advertising format, brands can work with publishers to develop content suited to established audience interests.
Furthermore, the partnerships allow one campaign story to appear in several contexts without losing its central message.
However, these collaborations must clearly distinguish paid promotional content from independent editorial coverage. Transparency remains essential when healthcare brands work with trusted media publishers.
How Social Media Extends the Campaign’s Reach
Publisher partnerships represent only part of Supernus’ approach.
According to Fierce Pharma’s October 28 coverage, the company is also emphasizing Meta platforms, TikTok, YouTube, and Snapchat to connect with younger audiences.
These platforms play different roles in a broader distribution strategy.
TikTok supports short, conversational content that can introduce a topic quickly. YouTube provides opportunities for longer discussions, while Snapchat reaches audiences through mobile-first experiences.
Meta platforms offer additional opportunities to distribute campaign messages across established social communities.
Importantly, these are identified campaign channels, not proof that every publisher collaboration appears on every platform.
The larger marketing principle is straightforward: Meet audiences where they already spend time.
For Qelbree, Kim serves as the recognizable connection between these environments. Someone might first encounter her story through a fashion feature, then see related content through a social platform.
That familiarity can make a campaign more recognizable across repeated encounters.
However, reaching an audience does not automatically establish engagement, awareness gains, or prescription impact. Those outcomes require measurement.
To understand what’s working, pharmaceutical marketers should look beyond impressions and track meaningful engagement, video completion rates, audience response, and visits to educational resources.
What Pharmaceutical Marketers Can Learn
The Qelbree campaign illustrates a shift from celebrity endorsement toward coordinated audience distribution.
Traditionally, pharmaceutical brands have often used recognizable personalities to strengthen commercials or awareness campaigns. In contrast, Kim’s partnership creates opportunities for different publishers to tell connected stories in formats suited to their audiences.
For marketers, several lessons stand out.
First, select spokespeople whose experiences genuinely connect with the campaign’s subject. Kim’s personal ADHD journey gives her participation relevance beyond athletic fame.
Second, choose publishers based on audience interests rather than reach alone. A fashion publication, wellness platform, and social video publisher can contribute distinct perspectives.
Third, develop content that fits each environment. Repurposing an identical advertisement everywhere may weaken the value of a publisher partnership.
Additionally, maintain a consistent central message while allowing appropriate differences in storytelling.
Finally, build compliance requirements into the distribution plan from the beginning.
The FDA’s prescription drug promotion guidance emphasizes truthful claims, appropriate risk disclosures, and a fair balance between benefit and risk information.
These requirements apply to regulated promotional content, including relevant social media advertising. Paid relationships must also be disclosed appropriately.
For Qelbree, which contains viloxazine extended-release, safety considerations include a boxed warning concerning increased risk of suicidal thoughts and behaviors. Celebrity storytelling cannot replace accurate product information.
More broadly, the campaign provides an example of how pharmaceutical advertisers can integrate publisher partnerships into their planning rather than treating editorial content as an isolated addition.
As Pharma Marketing continues to examine developments in healthcare advertising, campaigns like this highlight the growing importance of audience relevance, credible storytelling, and coordinated distribution.
Conclusion
Chloe Kim’s Qelbree campaign reflects an important development in pharmaceutical advertising.
Her role extends beyond appearing in advertisements. Through publisher collaborations and social media distribution, she connects different audience communities around a consistent story.
The real opportunity lies in building publisher partnerships that make branded healthcare content more relevant to the people receiving it. It’s not simply about appearing on more platforms. It’s about reaching the right audiences with stories that fit how they discover and discuss health information.
For pharmaceutical marketers, the lesson is clear: A spokesperson can become more valuable when the distribution strategy is built around the audiences they can credibly reach.
Frequently Asked Questions
What is publisher-led pharma marketing?
It uses partnerships with media publishers to develop and distribute healthcare content through established editorial and audience channels. This approach combines targeted distribution with formats suited to each publisher’s readership.
Why did Supernus Pharmaceuticals partner with Chloe Kim?
Supernus partnered with Kim to share her personal ADHD experience and help reach younger adult women through its “Ms. Represented” campaign. Her athletic profile and lifestyle interests also support wider audience connections.
Which publishers are involved in the Qelbree campaign?
The announced collaborations include Coveteur and PureWow, alongside a social-first interview with NowThis. Each provides a different setting for discussing Kim’s personal experiences.
How is this different from traditional celebrity drug advertising?
Traditional endorsements often center on a recognizable spokesperson appearing in advertisements. This campaign also places the spokesperson’s story within different publisher formats and digital communities, creating a connected distribution approach.
What should pharmaceutical marketers measure in publisher partnerships?
Useful measures include audience reach, engagement quality, content completion, educational resource visits, and awareness changes. Brands should also monitor disclosure practices, regulatory compliance, and whether content reaches its intended audience.
Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
